Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02918357 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence(PSMA BCR) | completed | Phase 2 / Phase 3 | 385 | University of California, San FranciscoOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT00582556 | Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy | completed | Phase 2 | 44 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 |
| clinicaltrials |
| NCT00214097 | Phase I/II Hypofractionated Radiotherapy for Prostate Cancer | completed | Phase 1 / Phase 2 | 347 | University of Wisconsin, MadisonOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00849121 | Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 17 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00488982 | Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 125 | University of California, San FranciscoOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03365297 | Therapeutics in Active Prostate Cancer Surveillance(TAPS01) | completed | Phase 2 | 11 | CCTU- Cancer ThemeOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00106418 | A Research Study for Patients With Prostate Cancer | completed | Phase 2 | 35 | CelgeneINDUSTRY | 0 | Nov 18, 2019 | clinicaltrials |
| NCT00030602 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | — | University of Maryland, BaltimoreOTHER | 0 | Nov 5, 2019 | clinicaltrials |
| NCT00003400 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 45 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00005028 | Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 46 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00456989 | Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 39 | University of LouisvilleOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01146340 | Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer(PHART6) | completed | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT01585246 | Saw Palmetto: Symptom Management for Men During Radiation Therapy | completed | Phase 1 / Phase 2 | 48 | Michigan State UniversityOTHER | 1 | Sep 30, 2019 | clinicaltrials |
| NCT01204710 | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | completed | Phase 2 | 123 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 20, 2019 | clinicaltrials |
| NCT01987999 | Eradication of Prostate Cancer Using F-989 | completed | Phase 2 | 60 | Optimal Health ResearchOTHER | 0 | Sep 20, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT00831792 | TKI258 in Castrate Resistant Prostate Cancer | completed | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02141490 | Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02279862 | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 9 | Aug 28, 2019 | clinicaltrials |
| NCT01083368 | Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy | completed | Phase 1 / Phase 2 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT03077659 | Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer | completed | Phase 2 | 16 | NanOlogy, LLCINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01243385 | Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | completed | Phase 2 | 44 | Swiss Cancer InstituteOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00976755 | Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 37 | Swiss Cancer InstituteOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT00714753 | Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01036321 | Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness | completed | Phase 2 | 71 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT00309894 | Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy | completed | Phase 2 | 49 | University of California, San FranciscoOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01084655 | Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00774436 | Study of Focal Cryoablation in Low-Risk Prostate Cancer | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT00669162 | Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Kansas Medical CenterOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT02796898 | Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 23 | Tyme, IncINDUSTRY | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01881867 | CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT01006395 | Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) | completed | Phase 2 / Phase 3 | 64 | Austin HealthOTHER_GOV | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01543776 | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | University of ChicagoOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT01867710 | Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy | completed | Phase 2 | 164 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 4 | Jul 5, 2019 | clinicaltrials |
| NCT00003259 | Vinorelbine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 40 | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT00006023 | Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT02057939 | Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)(STREAM) | completed | Phase 2 | 38 | Duke UniversityOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03543670 | Evaluation of Oncoxin-Viusid® in Prostate Cancer | completed | Phase 2 | 25 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT00728663 | Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 35 | Swiss Cancer InstituteOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT03573011 | PSMA PET/CT for Prostate Cancer(NGP2) | completed | Phase 2 | 64 | University Hospital, GhentOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT00528866 | Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | completed | Phase 2 | 80 | Radiation Therapy Oncology GroupNETWORK | 2 | Apr 24, 2019 | clinicaltrials |
| NCT00348595 | Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03081481 | Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer | completed | Phase 2 | 38 | Sophiris Bio CorpINDUSTRY | 2 | Apr 10, 2019 | clinicaltrials |
| NCT00642018 | A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer | completed | Phase 2 | 154 | Eli Lilly and CompanyINDUSTRY | 4 | Apr 3, 2019 | clinicaltrials |
| NCT00274287 | GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere | completed | Phase 2 | 15 | Oncology Specialists, S.C.OTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT01927627 | Enzalutamide in Patients With High-risk Prostate Cancer | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01487863 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 69 | DendreonINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2019source: clinicaltrials